Active	Status	Sponsor type	Region	Phase	Filter
18 Active 0 Inactive 18 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhong, Wangjian
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	Active, not recruiting	3	650	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib	Loxo Oncology, Inc., Eli Lilly and Company	Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma	02/25	08/28
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer	Recruiting	N/A	1050	Europe, US	Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay	Razor Genomics, Encore Clinical	Non-Small Cell Lung Cancer	05/27	05/27
Bylicki, Olivier
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer	Recruiting	N/A	1050	Europe, US	Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay	Razor Genomics, Encore Clinical	Non-Small Cell Lung Cancer	05/27	05/27
MESO-IMMUNE, NCT05308966: Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab	Active, not recruiting	N/A	200	Europe	Data collection	Groupe Francais De Pneumo-Cancerologie, Bristol-Myers Squibb	Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm	04/25	04/25
OBSTINATE, NCT05049044: Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC	Active, not recruiting	N/A	413	Europe	Quality of Life Questionnaire-Core 30 (QLQ-C30), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), 5-level EuroQoL EQ5D (EQ5D-5L)	Groupe Francais De Pneumo-Cancerologie, AstraZeneca	Non-Small Cell Lung Cancer	06/27	06/27
BIOEXALK, NCT05122806: Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC	Recruiting	N/A	100	Europe	RNAseq, DNA NGS	Groupe Francais De Pneumo-Cancerologie, Takeda	Non-small Cell Lung Cancer, ALK Gene Rearrangement Positive	06/27	06/27